Macter International Ltd.
PPSX:MACTER238.12
PKR
-5.88
(-2.41%)
Macter International Ltd.
PSX:MACTER
(Pakistan Stock Exchange)
Recent
price
238.12
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Macter International Limited is a Pakistan-based pharmaceutical and healthcare manufacturing company engaged in the development, formulation, production, marketing, and distribution of branded generic prescription pharmaceuticals, specialized hospital products, and consumer healthcare formulations. Founded in 1991 and headquartered in Karachi, Pakistan, the company operates current Good Manufacturing Practice (cGMP) compliant production facilities and serves commercial retail pharmacies, healthcare institutions, government tenders, armed forces hospitals, and international export markets across Asia, Africa, and the Middle East. The company's core product portfolio encompasses a broad spectrum of dosage forms and therapeutic classes, including oral solid dosage formulations such as tablets, capsules, and dry powder suspensions; liquid orals comprising syrups, elixirs, and oral drops; sterile parenteral formulations consisting of liquid ampoules, sterile vials, and lyophilized injectable powders; topical preparations including dermatological creams, ointments, and gels; and specialized respiratory inhalers and ophthalmic solutions. Its primary therapeutic segments include anti-infectives and broad-spectrum antibiotics, comprising cephalosporins, penicillins, macrolides, and fluoroquinolones; gastroenterology, offering proton pump inhibitors, antispasmodics, antiemetics, and laxatives; cardiovascular treatments, featuring antihypertensive agents, antianginals, and lipid-lowering statins; central nervous system (CNS) therapies, including non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, anxiolytics, and antidepressants; respiratory products, spanning bronchodilators, antihistamines, and anti-asthmatic agents; endocrinology and metabolic health, providing oral anti-diabetic medications and hormone replacements; specialized oncology and supportive care therapies; and nutritional healthcare, including therapeutic multivitamins, iron supplements, and nutraceutical preparations. In recent developments, Macter International Limited has advanced several strategic initiatives aimed at expanding its specialized manufacturing infrastructure, growing its international footprint, and diversifying into high-value biotherapeutic categories. The company has expanded its manufacturing capacity through the commissioning and validation of upgraded sterile injectable lines and automated lyophilization facilities designed to support hospital-grade critical care pharmaceuticals. To enhance its specialty product portfolio, Macter has entered into strategic technology transfer and licensing partnerships with international pharmaceutical developers for the domestic commercialization of biosimilars, oncology molecules, and specialized biotherapeutics. Geographically, the company has broadened its export operations by securing new distribution agreements and product registrations across emerging markets in Central Asia, East Africa, and the Middle East. Additionally, Macter has implemented operational efficiency and sustainability measures across its primary Karachi production complex, including the installation of industrial-scale rooftop solar power systems to optimize energy expenditures, improve grid resilience, and advance corporate sustainability goals.